Astellas Pharma
Dedicated to the development of high-quality peer-reviewed publications covering Astellas products that are compliant with applicable regulations and guidance.
Launch date
Employees
Market cap
$22.4b
Enterprise valuation
$26.3b (Public information from Sep 2024)
Share price
€10.58 YPH.F
Tokyo Japan (HQ)
Corporate Venture Fund: Astellas Venture
Financials
Estimates*
JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 1.2t | 1.3t | 1.5t | 1.6t | 1.8t | 1.8t | 1.9t |
% growth | (4 %) | 4 % | 17 % | 6 % | 9 % | 4 % | 7 % |
EBITDA | 220.3b | 217.3b | 246.7b | 185.1b | 324.1b | 389.6b | 465.5b |
% EBITDA margin | 18 % | 17 % | 16 % | 12 % | 19 % | 21 % | 24 % |
Profit | 120.6b | 124.1b | 98.7b | 17.0b | 78.4b | 141.4b | 214.6b |
% profit margin | 10 % | 10 % | 7 % | 1 % | 4 % | 8 % | 11 % |
EV / revenue | 2.3x | 2.5x | 2.0x | 1.6x | 2.1x | 2.0x | 1.8x |
EV / EBITDA | 12.8x | 14.7x | 12.2x | 14.1x | 11.6x | 9.6x | 7.7x |
R&D budget | 224.5b | 246.0b | 276.1b | 294.2b | - | - | - |
R&D % of revenue | 18 % | 19 % | 18 % | 18 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | Grant | ||
Total Funding | - |
Recent News about Astellas Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Astellas Pharma
EditACQUISITION by Astellas Pharma Oct 2016
ACQUISITION by Astellas Pharma Apr 2023
ACQUISITION by Astellas Pharma Apr 2020
ACQUISITION by Astellas Pharma Dec 2019
ACQUISITION by Astellas Pharma Dec 2007
exited
ACQUISITION by Astellas Pharma Apr 2017
ACQUISITION by Astellas Pharma Feb 2018